Printer Friendly

Amylyx to test lead therapeutic compound AMX0035 in partnership with Project ALS.

M2 EQUITYBITES-September 8, 2017-Amylyx to test lead therapeutic compound AMX0035 in partnership with Project ALS

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Pharmaceutical company Amylyx Pharmaceuticals reported on Thursday the launch of an agreement for the pre-clinical studies of its oral compound AMX0035 to advance the understanding of its neurobiological effects in partnership with Project ALS for the treatment of amyotrophic lateral sclerosis (ALS).

The studies, which will be conducted at the Project ALS Pre-Clinical Core at Columbia University's Motor Neuron Center, will complement Amylyx's recent Phase 2 clinical programme of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). The Core will accelerate the translation of new promising therapies to patients by facilitating speedy testing of new therapeutic leads discovered by laboratories studying motor neuron biology, genetics and genomics.

This collaboration is reportedly an outgrowth of previous studies by The Project ALS Pre-Clinical Core at Columbia University of tauroursodeoxycholic acid (TUDCA), one of the components of AMX0035.

According to the company, AMX0035 is a combination of two drugs, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). The AMX0035 has been shown to synergistically prevent nerve cell death and neurotoxic inflammation, hallmarks of ALS, in preclinical models.

Also known as Lou Gehrig's disease, ALS targets brain cells called motor neurons. Motor neurons send messages from the brain to muscles throughout the body. In ALS, as motor neurons weaken and die, a person progressively loses the ability to walk, speak, swallow, and breathe.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 8, 2017
Words:253
Previous Article:Rejlers extends two agreements with Agder Energi for a further two years.
Next Article:Arise reports power production of 38.7 GWh in August 2017.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters